Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigation of Nortase versus Kreon in severe exocrine pancreatic insufficiency using Pancreo-Lip 13C breath test
2016-005063-13Phase 4Completed
- Sponsor
- Repha
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of nortase and pancrelipase in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Repha. Primary endpoint: Total 13CO2-emission AUC 0–240 min (Nortase vs Kreon). Started Mar 2017; status: completed.
02
Drugs
nortasepancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2016-005063-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005063-13.